Pharmaceutical composition for reducing blood glucose and blood lipid and preparation method thereof

Through the composition of Rainbow Cyclops extract, Pyramid extract and compound extract, combined with a specific preparation process, the problem that existing treatments are difficult to reduce blood sugar and blood lipids at the same time is solved, and excellent glycemic and lowering are prepared. The pharmaceutical composition with lipid performance achieves the high efficiency and quality assurance of the drug.

CN119055706APending Publication Date: 2024-12-03HUBEI XIANG HU BIOLOGICAL ENG CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411250300.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Diabetes and hyperlipidemia are common clinical diseases. The existing treatment methods are difficult to effectively reduce blood sugar and blood lipids at the same time, which makes it difficult for patients to treat medication.

Method used

The composition of Rainbow Cyclops extract, Pyramid extract and composite extract is prepared by mixing and stirring and dry granulation through a specific preparation process to prepare a pharmaceutical composition with excellent glycemic and lipid-lowering properties.

Benefits of technology

This pharmaceutical composition not only significantly reduces the blood sugar and blood lipid levels of rats, ensures the quality and quality of the drug, and has a broader market prospect.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to a blood glucose and lipid lowering pharmaceutical composition and a preparation method thereof. The blood glucose and lipid lowering pharmaceutical composition is prepared from the following raw materials in parts by weight: 20 to 30 parts of haematococcus pluvialis extract, 10 to 15 parts of docynia delavayi bark extract and 5 to 10 parts of composite extract, the preparation method comprises the following steps: by taking a haematococcus pluvialis extract, a docynia delavayi extract, a composite extract and the like as raw materials, weighing the haematococcus pluvialis extract, the docynia delavayi extract and the composite extract, putting the haematococcus pluvialis extract, the docynia delavayi extract and the composite extract into mixing equipment, mixing and stirring, uniformly mixing, and performing dry granulation, thereby obtaining the haematococcus pluvialis-docynia delavayi capsule. And sieving to prepare the medicine composition for reducing blood sugar and blood fat. The blood glucose and lipid lowering pharmaceutical composition prepared by the invention not only has better blood glucose lowering performance, but also has excellent lipid lowering performance, and the quality of the blood glucose and lipid lowering pharmaceutical composition is effectively ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a blood sugar and lipid lowering pharmaceutical composition and a preparation method thereof. Background Art

[0002] Diabetes and hyperlipidemia are common clinical diseases. Continuous high blood sugar and long-term metabolic disorders can lead to damage to various tissues and organs throughout the body, as well as dysfunction and failure, seriously affecting the quality of life of patients. It is characterized by high blood sugar, decreased glucose tolerance, and insulin resistance, and is accompanied by a series of complications such as diabetic vascular disease, diabetic retinopathy, and diabetic nephropathy. Due to its complex causes, complications, and comorbidities, once it is contracted, the disease is long-lasting and cannot be cured. High blood sugar and high blood lipids promote each other, making it difficult for patients to be cured by medicine, and clinical treatment is very difficult.

[0003] Based on this, the present invention provides a hypoglycemic and lipid-lowering pharmaceutical composition and a preparation method thereof to solve the above-mentioned technical problems! Summary of the invention

[0004] The object of the present invention is to provide a hypoglycemic and lipid-lowering pharmaceutical composition and a preparation method thereof. The prepared hypoglycemic and lipid-lowering pharmaceutical composition not only has good hypoglycemic performance, but also has excellent lipid-lowering performance, effectively ensuring its quality.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] The first aspect of the present invention provides a hypoglycemic and lipid-lowering pharmaceutical composition, which is composed of the following raw materials in parts by weight: 20 to 30 parts of Haematococcus pluvialis extract, 10 to 15 parts of Codonopsis pilosula extract and 5 to 10 parts of a composite extract.

[0007] The present invention is further configured as follows: the preparation process of the Haematococcus pluvialis extract is as follows:

[0008] After washing and drying the Haematococcus pluvialis, placing the Haematococcus pluvialis in deionized water at a solid-liquid ratio of 0.01 to 0.09 g / mL, stirring for 10 to 12 minutes at 120 to 150 r / min, and then soaking for 30 to 40 minutes, and then adjusting the pH value to 4.2 to 4.4 with a 28 to 30% phosphoric acid solution to obtain a mixed solution, adding a composite enzyme to the mixed solution, and performing enzymolysis for 100 to 120 minutes to obtain an enzymolysis solution;

[0009] The enzymatic hydrolysate was subjected to ultrasonic treatment, microwave treatment, and centrifuged at 8000-9000 r / min for 30-40 min. The centrifuged product was freeze-dried to obtain the Haematococcus pluvialis extract.

[0010] The further setting of the present invention is that: the addition amount of the complex enzyme is 0.2-0.7% of the mass of the mixed solution, and the complex enzyme is composed of cellulase, pectinase and protease mixed in a mass ratio of 1:0.12-0.22:0.32-0.36.

[0011] The further setting of the present invention is that: the power of the ultrasonic treatment is 100-120 W, and the ultrasonic treatment time is 12-16 min.

[0012] The further setting of the present invention is that: the power of the microwave treatment is 320-340 W, and the microwave treatment time is 50-80 s.

[0013] The further setting of the present invention is that: the preparation process of the docynia indica peel extract is as follows:

[0014] Put the docynia indica peel into a pulverizing device and pulverize it to 100-200 meshes to obtain docynia indica peel powder. Place the docynia indica peel powder in an ethanol aqueous solution of 70-75% according to a solid-liquid ratio of 0.12-0.22 g / mL, and treat it under the condition of 320-330 r / min for 10-20 min;

[0015] Then raise the temperature to 52-55 °C, carry out ultrasonic extraction, filter by suction, and collect the supernatant. Concentrate it under vacuum at 45-50 °C, and finally freeze-dry to obtain the docynia indica peel extract.

[0016] The further setting of the present invention is that: the power of the ultrasonic extraction is 400-420 W, and the extraction time is 60-70 min.

[0017] The further setting of the present invention is that: the preparation process of the composite extract is as follows:

[0018] Place the composite material in deionized water according to a solid-liquid ratio of 0.02-0.12 g / mL for 100-120 min, then boil it for 120-140 min, filter by suction, and place the obtained filtrate in a vacuum concentrator for concentration;

[0019] Place the obtained concentrated product for freeze-drying to obtain the composite extract.

[0020] The further setting of the present invention is that: the composite material is prepared by compounding scrophularia root powder, rehmannia root powder and cortex lycii radicis powder in a mass ratio of 1:0.5-0.8:0.1-0.3.

[0021] The second aspect of the present invention: There is also provided a preparation method of the above hypoglycemic and lipid-lowering pharmaceutical composition, including the following steps:

[0022] Step 1. Accurately weigh the haematococcus pluvialis extract, docynia indica peel extract and composite extract, and put each of the haematococcus pluvialis extract, docynia indica peel extract and composite extract into a mixing device for mixing and stirring;

[0023] The mixing speed is 90-120 r / min and the time is 20-30 min.

[0024] Step 2: After the mixture is evenly mixed, dry granulation is performed and sifted to prepare a hypoglycemic and lipid-lowering pharmaceutical composition.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] In the present invention, the extract of Haematococcus pluvialis, the extract of the bark of euphorbia pulex and the composite extract are used as raw materials, and the extract of Haematococcus pluvialis, the extract of the bark of euphorbia pulex and the composite extract are weighed, and each of the extract of Haematococcus pluvialis, the extract of the bark of euphorbia pulex and the composite extract is put into a mixing device for mixing and stirring, and after being evenly mixed, dry granulation is performed, and sieving is performed to prepare a hypoglycemic and lipid-lowering pharmaceutical composition. The hypoglycemic and lipid-lowering pharmaceutical composition prepared by the present invention not only has good hypoglycemic performance, but also has excellent lipid-lowering performance, and effectively guarantees its quality and quality. The hypoglycemic and lipid-lowering pharmaceutical composition provided by the present invention and the preparation method thereof have a broader market prospect and are more suitable for promotion. DETAILED DESCRIPTION

[0027] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] Example 1

[0029] The present embodiment provides a hypoglycemic and lipid-lowering pharmaceutical composition, which is composed of the following raw materials in parts by weight: 20 parts of Haematococcus pluvialis extract, 10 parts of Codonopsis pilosula extract and 5 parts of a composite extract.

[0030] The preparation process of the Haematococcus pluvialis extract is as follows:

[0031] After washing and drying the Haematococcus pluvialis, the Haematococcus pluvialis was placed in deionized water at a solid-liquid ratio of 0.01 g / mL, stirred at 120 r / min for 10 min, and then soaked for 30 min, and then the pH value was adjusted to 4.2 with a 28% phosphoric acid solution to obtain a mixed solution, and a composite enzyme was added to the mixed solution, and enzymolysis was performed for 100 min to obtain an enzymolysis solution;

[0032] The enzymatic hydrolysate was subjected to ultrasonic treatment, microwave treatment, and centrifugation at 8000 r / min for 30 min. The centrifuged product was freeze-dried to obtain the Haematococcus pluvialis extract.

[0033] Furthermore, the addition amount of the complex enzyme is 0.2% of the mass of the mixed solution, and the complex enzyme is composed of cellulase, pectinase, and protease mixed in a mass ratio of 1:0.12:0.32.

[0034] Furthermore, the power of the ultrasonic treatment is 100 W, and the ultrasonic treatment time is 12 min.

[0035] The power of the microwave treatment is 320 W, and the microwave treatment time is 50 s.

[0036] Among them, the preparation process of the Docynia indica peel extract is as follows:

[0037] Put the Docynia indica peel into a crushing device and crush it to 100 meshes to obtain Docynia indica peel powder. Place the Docynia indica peel powder in a 70% ethanol aqueous solution according to a solid-liquid ratio of 0.12 g / mL, and treat it for 10 min under the condition of 320 r / min;

[0038] Then raise the temperature to 52 °C, perform ultrasonic extraction, filter by suction, and collect the supernatant. Concentrate it under vacuum at 45 °C, and finally freeze-dry it to obtain the Docynia indica peel extract.

[0039] Furthermore, the power of the ultrasonic extraction is 400 W, and the extraction time is 60 min.

[0040] In addition, the preparation process of the composite extract is as follows:

[0041] Place the composite material in deionized water according to a solid-liquid ratio of 0.02 g / mL for 100 min, then boil it for 120 min. After filtering by suction, place the obtained filtrate in a vacuum concentrator for concentration;

[0042] Place the obtained concentrated product in a freeze dryer to obtain the composite extract.

[0043] Furthermore, the composite material is prepared by compounding scrophularia powder, rehmannia powder, and lycium chinense miller bark powder in a mass ratio of 1:0.5:0.1.

[0044] In addition, this embodiment also provides a preparation method of the above hypoglycemic and lipid-lowering pharmaceutical composition, including the following steps:

[0045] Step 1: Accurately weigh the Haematococcus pluvialis extract, Docynia indica peel extract, and composite extract, and put each of the Haematococcus pluvialis extract, Docynia indica peel extract, and composite extract into a mixing device for mixing and stirring;

[0046] Among them, the rotation speed of the mixing and stirring is 90 r / min, and the time is 20 min;

[0047] Step 2: After mixing evenly, perform dry granulation and sieving to prepare the hypoglycemic and lipid-lowering pharmaceutical composition.

[0048] Example 2

[0049] The present embodiment provides a hypoglycemic and lipid-lowering pharmaceutical composition, which is composed of the following raw materials in parts by weight: 25 parts of Haematococcus pluvialis extract, 12 parts of Codonopsis pilosula extract and 7 parts of a composite extract.

[0050] The preparation process of the Haematococcus pluvialis extract is as follows:

[0051] After washing and drying the Haematococcus pluvialis, the Haematococcus pluvialis was placed in deionized water at a solid-liquid ratio of 0.04 g / mL, stirred at 135 r / min for 11 min, and then soaked for 35 min, and then the pH value was adjusted to 4.3 with a 29% phosphoric acid solution to obtain a mixed solution, and a composite enzyme was added to the mixed solution, and enzymolysis was performed for 110 min to obtain an enzymolysis solution;

[0052] The enzymatic hydrolysate was subjected to ultrasonic treatment, microwave treatment, and centrifugation at 8500 r / min for 35 min. The centrifuged product was freeze-dried to obtain the Haematococcus pluvialis extract.

[0053] Furthermore, the added amount of the complex enzyme is 0.4% of the mass of the mixed solution, and the complex enzyme is a mixture of cellulase, pectinase and protease in a mass ratio of 1:0.17:0.34.

[0054] Furthermore, the power of the ultrasonic treatment was 110 W, and the ultrasonic treatment time was 14 min.

[0055] The power of the microwave treatment was 330 W, and the microwave treatment time was 65 s.

[0056] The preparation process of the extract of the radix scutellariae is as follows:

[0057] The bark of bayi was crushed into 150 meshes in a crushing device to obtain bark of bayi powder, and the bark of bayi powder was placed in a 72% ethanol aqueous solution at a solid-liquid ratio of 0.17 g / mL, and treated at 325 r / min for 15 min;

[0058] The temperature was then raised to 53°C, and after ultrasonic extraction, the mixture was filtered and the supernatant was collected. The mixture was vacuum concentrated at 47°C and finally freeze-dried to obtain the extract of the bark of the mulberry tree.

[0059] Furthermore, the power of ultrasonic extraction was 410 W, and the extraction time was 65 min.

[0060] Furthermore, the preparation process of the composite extract is as follows:

[0061] The composite material was placed in deionized water at a solid-liquid ratio of 0.07 g / mL for 110 min, then boiled in water for 130 min, and after filtration, the filtrate was concentrated in a vacuum concentrator;

[0062] The concentrated product was freeze-dried to obtain a composite extract.

[0063] Furthermore, the composite material is prepared by mixing Scrophularia ningpoensis powder, Rehmannia glutinosa powder and Cortex Lycii Root powder in a mass ratio of 1:0.6:0.2.

[0064] In addition, this embodiment also provides a method for preparing the above-mentioned hypoglycemic and lipid-lowering pharmaceutical composition, comprising the following steps:

[0065] Step 1, accurately weighing the Haematococcus pluvialis extract, the Coix lacryma-jobi extract and the composite extract, and putting the Haematococcus pluvialis extract, the Coix lacryma-jobi extract and the composite extract into a mixing device for mixing and stirring;

[0066] The mixing speed is 105 r / min and the time is 25 min.

[0067] Step 2: After the mixture is evenly mixed, dry granulation is performed and sifted to prepare a hypoglycemic and lipid-lowering pharmaceutical composition.

[0068] Example 3

[0069] The present embodiment provides a hypoglycemic and lipid-lowering pharmaceutical composition, which is composed of the following raw materials in parts by weight: 30 parts of Haematococcus pluvialis extract, 15 parts of Codonopsis pilosula extract and 10 parts of a composite extract.

[0070] The preparation process of the Haematococcus pluvialis extract is as follows:

[0071] After washing and drying the Haematococcus pluvialis, the Haematococcus pluvialis was placed in deionized water at a solid-liquid ratio of 0.09 g / mL, stirred at 150 r / min for 12 min, and then soaked for 40 min, and then the pH value was adjusted to 4.4 with a 30% phosphoric acid solution to obtain a mixed solution, and a composite enzyme was added to the mixed solution, and enzymolysis was performed for 120 min to obtain an enzymolysis solution;

[0072] The enzymatic hydrolysate was subjected to ultrasonic treatment, microwave treatment, and centrifugation at 9000 r / min for 40 min. The centrifuged product was freeze-dried to obtain the Haematococcus pluvialis extract.

[0073] Furthermore, the added amount of the complex enzyme is 0.7% of the mass of the mixed solution, and the complex enzyme is a mixture of cellulase, pectinase and protease in a mass ratio of 1:0.22:0.36.

[0074] Furthermore, the power of the ultrasonic treatment was 120 W, and the ultrasonic treatment time was 16 min.

[0075] The power of the microwave treatment was 340 W, and the microwave treatment time was 80 s.

[0076] Among them, the preparation process of Docynia indica (Wall.) Decne. peel extract is as follows:

[0077] Put Docynia indica (Wall.) Decne. peel into a crushing device and crush it to 200 meshes to obtain Docynia indica (Wall.) Decne. peel powder. Place the Docynia indica (Wall.) Decne. peel powder in 75% ethanol aqueous solution according to the solid-liquid ratio of 0.22 g / mL, and treat it for 20 min under the condition of 330 r / min;

[0078] Then raise the temperature to 55 °C, carry out ultrasonic extraction, suction filtration, and collect the supernatant. Vacuum concentrate it under the condition of 50 °C, and finally freeze-dry to obtain Docynia indica (Wall.) Decne. peel extract.

[0079] Furthermore, the power of ultrasonic extraction is 420 W, and the extraction time is 70 min.

[0080] In addition, the preparation process of the composite extract is as follows:

[0081] Place the composite material in deionized water according to the solid-liquid ratio of 0.12 g / mL for 120 min, then boil it for 140 min. After suction filtration, place the obtained filtrate in a vacuum concentrator for concentration;

[0082] Place the obtained concentrated product for freeze-drying to obtain the composite extract.

[0083] Furthermore, the composite material is prepared by compounding scrophularia root powder, rehmannia root powder and cortex lycii radicis powder according to the mass ratio of 1:0.8:0.3.

[0084] In addition, this embodiment also provides a preparation method of the above hypoglycemic and lipid-lowering pharmaceutical composition, including the following steps:

[0085] Step 1. Accurately weigh the extract of Haematococcus pluvialis, Docynia indica (Wall.) Decne. peel extract and composite extract, and put each of the extract of Haematococcus pluvialis, Docynia indica (Wall.) Decne. peel extract and composite extract into a mixing device for mixing and stirring;

[0086] Among them, the rotation speed of mixing and stirring is 120 r / min, and the time is 30 min;

[0087] Step 2. After mixing evenly, carry out dry granulation and sieving to prepare the hypoglycemic and lipid-lowering pharmaceutical composition.

[0088] Performance test: Mark the hypoglycemic and lipid-lowering pharmaceutical compositions provided in Examples 1-3 as Examples 1-3 respectively; and conduct the following tests on the relevant performances of the hypoglycemic and lipid-lowering pharmaceutical compositions provided in Examples 1-3 respectively:

[0089] Hypoglycemic and lipid-lowering test: Feed SD rats with high-sugar and high-fat feed to induce an insulin resistance model. Take 40 successfully modeled rats, randomly divide them into 4 groups. Among them, there are 10 rats in the control group, and the remaining 3 groups are respectively gavaged with the hypoglycemic and lipid-lowering pharmaceutical compositions of Examples 1-3, at 0.3 g·kg -1The control group was given a corresponding dose of tap water. Each group continued to be fed with a high-sugar and high-fat diet. At the 10th week of intragastric administration, a semi-automatic biochemical analyzer was used to measure the total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-L) in the rats' serum. At the 10th week of intragastric administration, the tails were cut to collect blood, and the blood glucose of the rats was measured using a blood glucose meter and blood glucose test strips.

[0090] The obtained test data are recorded in Table 1 and Table 2 below:

[0091] Table 1 Test results of lipid-lowering performance of each group

[0092] Group TC(mol / L) TG(mol / L) HDL-C (mol / L) LDL-L (mol / L) Control group 4.25 1.08 2.35 0.18 Example 1 Group 2.94 0.93 2.71 0.65 Example 2 Group 2.91 0.92 2.65 0.61 Example 3 Group 2.94 0.92 2.68 0.67

[0093] Table 2 Test results of hypoglycemic performance of each group

[0094] Group Blood glucose (mol / L) Control group 13.74 Example 1 Group 16.62 Example 2 Group 17.21 Example 3 Group 16.91

[0095] By comparing and analyzing the relevant data in Table 1 and Table 2, it can be seen that the hypoglycemic and lipid-lowering pharmaceutical composition prepared by the present invention not only has good hypoglycemic performance, but also has excellent lipid-lowering performance, effectively ensuring its quality and quality. This shows that the hypoglycemic and lipid-lowering pharmaceutical composition and the preparation method thereof provided by the present invention have a broader market prospect and are more suitable for promotion.

[0096] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0097] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.

Claims

1. A hypoglycemic and lipid-lowering pharmaceutical composition, characterized in that: It is composed of the following raw materials in parts by weight: 20 - 30 parts of Haematococcus pluvialis extract, 10 - 15 parts of Docynia indica peel extract, and 5 - 10 parts of compound extract.

2. A glucose-lowering and lipid-lowering pharmaceutical composition according to claim 1, characterized in that: The preparation process of the Haematococcus pluvialis extract is as follows: After cleaning and drying the Haematococcus pluvialis, place the Haematococcus pluvialis in deionized water according to a solid - liquid ratio of 0.01 - 0.09 g / mL, stir at 120 - 150 r / min for 10 - 12 min, then soak for 30 - 40 min, and then adjust the pH value to 4.2 - 4.4 with a phosphoric acid solution with a concentration of 28 - 30% to obtain a mixed solution. Add compound enzyme to the mixed solution and enzymolyze for 100 - 120 min to obtain an enzymolyzed solution; After ultrasonic treatment of the enzymolyzed solution, then microwave treatment, and centrifuge at 8000 - 9000 r / min for 30 - 40 min, and freeze - dry the obtained centrifuged product to obtain the Haematococcus pluvialis extract.

3. A glucose-lowering and lipid-lowering pharmaceutical composition according to claim 2, characterized in that: The addition amount of the compound enzyme is 0.2 - 0.7% of the mass of the mixed solution, and the compound enzyme is composed of cellulase, pectinase, and protease mixed in a mass ratio of 1:0.12 - 0.22:0.32 - 0.

36.

4. A hypoglycemic and lipid-lowering pharmaceutical composition according to claim 2, characterized in that: The power of the ultrasonic treatment is 100 - 120 W, and the ultrasonic treatment time is 12 - 16 min.

5. A hypoglycemic and lipid-lowering pharmaceutical composition according to claim 2, characterized in that: The power of the microwave treatment is 320 - 340 W, and the microwave treatment time is 50 - 80 s.

6. A glucose-lowering and lipid-lowering pharmaceutical composition according to claim 1, characterized in that: The preparation process of the Docynia indica peel extract is as follows: Place the Docynia indica peel in a pulverizing device and pulverize it to 100 - 200 mesh to obtain Docynia indica peel powder. Place the Docynia indica peel powder in a 70 - 75% ethanol aqueous solution according to a solid - liquid ratio of 0.12 - 0.22 g / mL, and treat it at 320 - 330 r / min for 10 - 20 min; Then raise the temperature to 52 - 55 °C, after ultrasonic extraction, filter by suction, and collect the supernatant. Vacuum - concentrate it at 45 - 50 °C, and finally freeze - dry it to obtain the Docynia indica peel extract.

7. A glucose-lowering and lipid-lowering pharmaceutical composition according to claim 6, characterized in that: The power of the ultrasonic extraction is 400 - 420 W, and the extraction time is 60 - 70 min.

8. The glucose-lowering and lipid-lowering pharmaceutical composition according to claim 1, characterized in that: The preparation process of the compound extract is as follows: Place the compound material in deionized water according to a solid - liquid ratio of 0.02 - 0.12 g / mL for 100 - 120 min, then boil it for 120 - 140 min. After suction filtration, place the obtained filtrate in a vacuum concentrator for concentration; Place the obtained concentrated product for freeze - drying to obtain the compound extract.

9. A glucose-lowering and lipid-lowering pharmaceutical composition according to claim 8, characterized in that: The compound material is compounded by Scrophularia ningpoensis powder, Rehmannia glutinosa powder, and Cortex Lycii Radicis powder in a mass ratio of 1:0.5 - 0.8:0.1 - 0.

3.

10. A method for preparing a hypoglycemic and lipid-lowering pharmaceutical composition according to any one of claims 1 to 9, characterized in that: It includes the following steps: Step 1: Accurately weigh the Haematococcus pluvialis extract, Docynia indica peel extract, and compound extract, and put each of the Haematococcus pluvialis extract, Docynia indica peel extract, and compound extract into a mixing device for mixing and stirring; Among them, the rotation speed of the mixing and stirring is 90 - 120 r / min, and the time is 20 - 30 min; Step 2: After mixing evenly, perform dry granulation and sieving to prepare the hypoglycemic and lipid - lowering pharmaceutical composition.

Citation Information

Patent Citations

  • Rehmanniae thirstiness-dispelling tea

    CN101204465A

  • Application of Docynia Dcne plant leaves and extract thereof in preparing medicine for preventing and treating abnormal lipid metabolism

    CN105770059A

  • Haematococcus tablet candy capable of reducing blood pressure, reducing blood sugar, reducing uric acid and resisting tumor, and application thereof

    CN107836558A

  • Haematococcus pluvialis extract with deep repair function and preparation method of haematococcus pluvialis extract with deep repair function

    CN108703978A

  • Haematococcus pluvialis wall-broken powder and preparation method thereof

    CN115736250A